Plain-English translation of NCT07250542 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Prostate Cancer research guide โPhase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether Fasudil Hydrochloride, when combined with a type of immunotherapy called a PD-1 inhibitor, can help treat advanced prostate cancer that has stopped responding to standard hormone therapy. You would receive this medication combination along with your regular hormone treatment. The goal is to see if this new approach slows or stops the cancer's growth.
Many men with advanced prostate cancer eventually develop a form that no longer responds to standard hormone treatments, and options become limited. This study is exploring whether this new medication combination might help patients whose cancer has reached this difficult stage.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this trial, you would receive intravenous infusions of the medication over 5 days, followed by an immunotherapy infusion on day 5. This cycle repeats every 21 days for a total of 4 treatment cycles (about 3 months). You would continue your regular hormone therapy throughout. The study involves blood tests and imaging scans to monitor how your cancer responds to the treatment.
AI-generated summary from trial data ยท Jun 24, 2026 ยท Not medical advice
China